InflaRx N.V. (IFRX)
BiotechSign Signal Grade
Composite of clinical trial activity, dilution exposure, publications, short interest, and insider transactions — all from verified public filings.
Pipeline Overview
- Therapeutic Focus
- Biotech / Pharmasrc
Clinical Trial Activity
(ClinicalTrials.gov aggregate)
ClinicalTrials.gov aggregate as of 2026-10-13. ClinicalTrials.gov
Dilution Risk
MEDIUM DILUTION RISKDilution score: 47/100 (MEDIUM), cash runway not available
Derived from verified regulatory filings. Measures dilution exposure from warrants, convertibles, and offering history. DilutionWatch SEC-derived score
Short Interest
Short interest: 22.28% of float, squeeze risk: HIGH
FINRA short sale data. FINRA short interest
Recent News & SEC Filings
- InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026
- InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development
- InflaRx Announces Participation in September Investor Conferences
- InflaRx Reports Second Quarter 2026 Results and Highlights Key Achievements and Expected Milestones
- InflaRx Assessing Feasibility of Broadened Strategy for ANCA‑Associated Vasculitis in Europe Following EMA Recommendation on Tavneos
- Here’s Why InflaRx (IFRX) is Among the 10 Most Volatile Penny Stocks to Buy Now
- InflaRx Investor Update: Izicopan Set to Take Center Stage in AAV and Renal Disease Pipeline
- InflaRx to Report First Quarter 2026 Results on May 7, 2026
Headlines from public sources. BiotechSign does not endorse or verify linked content.
Get real-time catalyst alerts, analyst signals, dilution risk tracking, and full pipeline data for InflaRx N.V..
Full IFRX Dashboard Sign Up FreePrimary Sources
This page reports only records present in the BiotechSign source payload as of the generation date. It does not infer drug efficacy, clinical outcome probability, approval odds, revenue, market size, or unreported regulatory events.